Skip to main content

Farmacología humana, potencial de abuso y evaluación de la conectividad neuronal del hexahidrocannabinol en comparación con el tetrahidrocannabinol

PI24/00660

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i en Salud
Call year 2024
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL
Execution centre INSTITUTO DE INVESTIGACION GERMANS TRIAS I PUJOL (IGTP)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in Humans

  • Caicedo di Filippo, Dolly Andrea|||0009-0009-6523-0265
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Papaseit, Esther|||0000-0003-2620-4274
Cannabis is the most commonly used illicit substance worldwide. Recent years have seen an increase in cannabis consumption, and with new approvals and therapeutic indications, there are challenges in minimizing the risks and interactions between cannabis-based products, cannabis prescription drugs, other approved prescription drugs, and other substances of abuse. Thus, identifying the enzymes metabolizing cannabinoid drugs and their relationship with other prescription drugs is crucial for understanding the potential interactions and effects of their simultaneous use. This article offers a comprehensive review of cannabis and the pharmacokinetic interactions between cannabis products, cannabis prescription drugs, and other approved prescription drugs, as well as other substances of abuse. It also compiles existing evidence of these interactions and describes the clinical outcomes associated with the inhibition or induction of various enzymes.